Download file : lavori per esteso

1
PUBBLICAZIONI DAL 1985 - 2014
Tonato M., Roila F., Del Favero A., Tognoni G., Franzosi M.G., Pampallona S. for the Italian Clinical Research
Oncology Group (GOIRC):
A pilot study of high dose domperidone as antiemetic in patients treated with cisplatin.
European Journal of Cancer 21, 807-810, 1985. (IF=4.121)
Roila F., Tonato M., Basurto C., Ballatori E., Del Favero A., Tognoni G., Franzosi M.G., Passalacqua R. for the Italian
Clinical Research Oncology Group (GOIRC):
Antiemetic activity of two different high doses of metoclopramide (MTC) in cisplatin treated cancer patients. A
randomized double blind trial.
Cancer Treatment Reports. 69, 1353-1357, 1985. (IF=5.295)
Cocconi G., Tonato M., Di Costanzo F., Bisagni G., Belsanti V., Buzzi F., Ceci G.:
Platinum and Etoposide in chemotherapy refractory metastatic breast cancer. A phase II trial of the Italian Oncology
Group for Clinical Research (GOIRC).
European Journal of Cancer and Clinical Oncology 22:761-764, 1986. (IF=4.121)
De Lisi V., Cocconi G., Tonato M., Di Costanzo F., Leonardi F., Soldani M.:
Randomized comparison of 5-FU alone or combined with carmustine, doxorubicin and mitomycin (BAFMI) in the
treatment of advanced gastric cancer. A phase III trial of the Italian Oncology Group for Clinical Research (GOIRC).
Cancer Treatment Reports 70:481-485, 1986. (IF=5.295)
Roila F., Tonato M., Basurto C, Bella M., Passalacqua R., MorsiaD., Di Costanzo F., Donati D., Ballatori A., Tognoni G.,
A. Del Favero:
Antiemetic activity of high doses of metoclopramide combined with metylprednisolone alone in cisplatin treated cancer
patients: a randomized double blind trial the Italian Oncology Group for Clinical Research (GOIRC).
Journal of Clinical Oncology. 5: 141-149, 1987 (IF=17.793)
Bacchi M.:
La conduzione di uno studio multicentrico: esperienza GOIRC
in “Sillabo XII Corso di Aggiornamento in Oncologia Medica” a cura dell’AIOM, Gestioni Grafiche Stocchiero Ed.,
Vicenza; pp 109-128, 1988
De Lisi V., Cocconi G., Tonato M., Di Costanzo F., Leonardi F., Soldani M.:
5-Fluorouracil versus a combination of BCNU, adriamycin, 5-FU and mitomycin C in advanced gastric cancer: a
prospective randomized study the Italian Oncology Group for Clinical Research (GOIRC).
Recent Results in Cancer Research, 110:212-218, 1988.
Passalacqua R., Bisagni G., Bertusi M., Donati D., Buzzi F., Di Costanzo F., Basurto C., Gori S.:
Lonidamine in advanced colorectal cancer: a phase II trial of the Italian Oncology Group for Clinical Research (GOIRC).
Tumori 75:277-279, 1989 (IF=0.863)
Roila F., Tonato M., Basurto C., Picciafuoco M., Bracarda S., Donati D., Malacarne P., Monici L., Di Costanzo F., Patoia
L., Ballatori E., Tognani G., Del Favero A.:
Protection from nausea and vomiting in cisplatin-treated patients: high-dose metoclopramide combined with
methylprednisolone versus metoclopramide combined with dexamethasone and diphenhydramine. A study of the Italian
Oncology Group for Clinical Research.
Journal of Clinical Oncology 7:1693-1700, 1989. (IF=17.793)
Di Costanzo F., Bartolucci R., Sofra M., Calabresi F., Malacarne P., Belsanti V., Boni C., Bacchi M.:
5-fluorouracile vs alte dosi di acido folico e 5-fluorouracile nel carcinoma del colon-retto avanzato. Studio randomizzato
del Gruppo Oncologico Italiano di Ricerca Clinica (GOIRC)
Atti “Nuove prospettive in Oncologia – L’associazione Fluorouracile e Folati”, a cura di F. Di Costanzo, Arti Grafiche
Nobili Ed. Terni, pp: 71-80, 1990
2
Cocconi G., Di Costanzo F., Bisagni G., Bacchi M., Buzzi F., Canaletti R., Carpi A., Ceci G., Colozza A., De Lisi V.,
Lottici R., Passalacqua R., Peracchia G.:
Confronto fra la continuazione della chemioterapia di induzione ed una intensificazione tardiva seguita dalla sospensione
di ogni chemioterapia nel carcinoma mammario metastatizzato. Studio randomizzato del Gruppo Oncologico Italiano di
Ricerca Clinica (GOIRC)
Proc. “Advances in management of malignancies – 2nd International Congress promoted by Fondazione Internazionale
Menarini” a cura di A. Carpi, A. Sagripanti, B. Grassi, Monduzzi Ed. Bologna, pp: 407-419, 1990
Cocconi G., Bisagni G., Bacchi M., Buzzi F., Canaletti R., Carpi A., Ceci G., Colozza A., De Lisi V., Lottici R.,
Passalacqua R., Peracchia G.
A comparison of continuation versus late intensification followed by discontinuation of chemotherapy in advanced breast
cancer. A prospective randomized trial of the Italian Oncology Group for Clinical Research (GOIRC).
Annals of Oncology 1: 36-44, 1990 (IF=5.647)
Cocconi G., Lottici R., Bisagni G., Bacchi M., Tonato M., Passalacqua R., Boni C., Belsanti V., Bassi P.
Combination therapy with platinum and etoposide of brain metastases from breast carcinoma.
Cancer Investigation, 8: 327-334, 1990
Cocconi G., Bisagni G, Bacchi M, Boni C, Bartolucci R, Ceci G, Colozza MA, De Lisi V, Lottici R, Mosconi AM,
Passalacqua R, Tonato M.
Cisplatin and etoposide as first-line chemotherapy for metastatic breast carcinoma: a prospective randomized study the
Italian Oncology Group for Clinical Research.
Journal of Clinical Oncology, 9:664-669, 1991 (IF=17.793)
Di Costanzo F., Malacarne P., Zironi S., Marzola M., Corgna E., Figoli F., Bacchi M., Passalacqua R., Algeri R.,
Bartolucci R.
Preliminary report of high dose of folinic acid and 5-Fluorouracil alone or combined with hydroxyurea in advanced
colorectal cancer: a randomized trial of the Italian Oncology Group for Clinical Research.
Journal of Surgical Oncology, Suppl. 2: 137-140, 1991
Cocconi G., Bisagni G., Ceci G., Bacchi M., Boni C., Brugia M., Carpi A., Di Costanzo F., Franciosi V., Gori S., Indelli
M., Passalacqua R.
Low-dose aminogluthetimide with and without hydrocortisone replacement as a first-line endocrine treatment in
advanced breast cancer: a prospective randomized trial of the Italian Oncology Group for Clinical Research
Journal of Clinical Oncology 10:984-989, 1992 (IF=17.793)
Di Costanzo F., Bartolucci R., Calabresi F., Sofra M., Marzola M., Belsanti V., Boni C., Bacchi M.
Fluorouracil-alone versus high-dose folinic acid and fluorouracil in advanced colorectal cancer: a randomized trial of the
Italian Oncology Group for Clinical Research (GOIRC).
Annals of Oncology, 3:371-376, 1992. (IF=5.647)
Cocconi G., Bella M., Calabresi F., Tonato M., Canaletti R., Boni C., Buzzi F., Ceci G., Corgna E., Costa P., Lottici R.,
Papadia F., Sofra M., Bacchi M.
Treatment of metastatic malignant melanoma with dacarbazine plus tamoxifen.
New England Journal of Medicine 327: 516-523, 1992. (IF=47.050)
Di Costanzo F.
Best treatment for colorectal cancer and confirmatory trials.
Annals of Oncology 3 (3): 245-246, 1992. (IF=5.647)
Bisagni G., Cocconi G., Ceci G., De Lisi V., Di Blasio B., Lottici R., Passalacqua R., Finardi C.
M-VAC combination in locally advanced, locally recurrent or metastatic breast carcinoma. A phase II study.
Annals of Oncology, 5: 93-94, 1994. (IF=5.647)
Cocconi G., Bella M., Zironi S., Algeri R., Di Costanzo F., De Lisi V., Luppi G., Mazzocchi B., Rodinò C., Soldani M.,
Gilli G., Finardi C.
Fluorouracil, Doxorubicin, and Mitomycin combination versus PELF chemotherapy in advanced gastric cancer: A
prospective randomized trial of the Italian Oncology Group for Clinical Research.
Journal of Clinical Oncology 12: 2687-2693, 1994. (IF=17.793)
3
Cocconi G, Bisagni G, Ceci G, Bacchi M:
Aminoglutethimide: the problem of the optimal dose and the indispensability or not of hydrocortisone.
In "Clinical use of aromatase inhibitors. Current data and future prospective",
G. Robustelli Della Cuna, A. Manni, F. Pannuti, EDIMES Ed., Pavia, pp. 97-105, 1994
Ceci G., Bisagni G., Cocconi G., Rodinò C., Belsanti V., Bertusi M., Buzzi F., Bacchi M.:
Cisplatin and VP16 in metastatic breast carcinoma as a third line chemotherapy. A randomized study comparing low vs
high doses of Cisplatin.
Tumori 81: 241-244, 1995
Crinò L., Clerici M., Figoli F., Carlini P., Ceci G., Cortesi E., Carpi A., Santini A., Di Costanzo F., Boni C., Meacci M.,
Corgna E., Darwish S., Scarcella L., Santucci A., Ballatori E., Tonato M.
Chemotherapy of advanced non-small-cell lung cancer: a comparison of three active regimens. A randomized trial of the
Italian Oncology Group for Clinical Research (GOIRC)
Annals of Oncology 6: 347-353, 1995. (IF=5.647)
Crinò L., Clerici M., Figoli F., Barduagni M., Carlini P., Ceci G., Cortesi E., Carpi A., Santini A., Di Costanzo F. et al.
Superiority of three-drug combination chemotherapy versus cisplatin-etoposide in advanced non-small cell ling cancer: a
randomized trial by the Italian Oncology Group for Clinical Research.
Lung Cancer 12 (suppl 1): S125-132, 1995.
De Lisi V., Cocconi G., Angelini F., Cavicchi F., Di Costanzo F., Gilli G., Rodinò C., Soldani M., Tonato M., Finardi C.
The combination of cisplatin, doxorubicin, and mitomycin (PAM) compared with the FAM regimen in treating advanced
gastric carcinoma.
Cancer 77: 245-250, 1996.
Di Costanzo F., Tagliaventi M., Carlini P., Zironi S., Mazzocchi B., Bella M., Donati D., Acito L., Maggian P., Angiona
S.
High-dose folinic acid and fluorouracil with or without ifosfamide is an inactive combination in advanced pancreatic
cancer. A randomized phase II study of the Italian Oncology Group for Clinical Research (GOIRC).
American Journal of Clinical Oncology 19 (3): 307-310, 1996.
Di Costanzo F., Gasperoni S., Labianca R., Sdrobolini A., Zamparelli G., Angiona S., Bartolucci R., Rossetti R. on behalf
of GOIRC and GISCAD.
Preliminary report of an ongoing trial comparing surgery alone versus surgery and chemotherapy in operable gastric
cancer.
Journal of Chemotherapy 8 suppl. 4: 104-106, 1996.
Passalacqua R., Cocconi G., Caminiti C., Silingardi V., Bella M.A., Bichisao E., Michiara M., Malavasi V., Donati D., Di
Costanzo F., Rocca A., Di Sarra S., Scaglione F., Fraschini F.
Double-blind , multicenter, randomized trial to compare the effect of two doses of adrenocorticotropic hormone versus
placebo in controlling delayed emesis after high-dose cisplatin in adult patients.
Journal of Clinical Oncology 15: 2467-2473, 1997. (IF=17.793)
Di Costanzo F., Gasperoni S., Malacarne P., Belsanti V., Luppi G., Marzola M., Corgna E., Sdrobolini A., Passalacqua
R., Figoli F., Algeri R., Zironi S., Angiona S., Boni C.
High-dose folinic acid and 5-fluorouracil alone or combined with hydroxyurea in advanced colorectal cancer: a
randomized trial of the Italian Oncology Group for Clinical Research.
American Journal of Clinical Oncology 21 (4): 369-375, 1998.
Boni C., Savoldi L., Bisagni G., Ceci G., Crinò L., De Lisi V., Di Costanzo F., Lasagni L., Manenti AL., Moretti G.,
Rondini E., Sassi M., Zadro A.
Bolus versus 5-day continuous infusion of cisplatin with mitomycin and vindesine in the treatment of advanced non-small
cell lung cancer (NSCLC): a phase III prospective randomised trial of the Italian Oncology Group for Clinical Research
(GOIRC).
European Journal of Cancer 34 (12): 1974-1976, 1998. (IF=4.121)
Franciosi V., Cocconi G., Michiara M., Di Costanzo F., Fosser V., Tonato M., Carlini P., Boni C., Di Sarra S.
Front-line chemotherapy with cisplatin and etoposide for patients with brain metastases from breast carcinoma, non small
cell lung carcinoma, or malignant melanoma.
Cancer 85: 1599-1605, 1999
4
Cocconi G., Bisagni G., Ceci G., Di Blasio B., De Lisi V., Passalacqua R., Zadro A., Boni C., Morandi P., Savoldi L.:
Three new highly active cisplatin-containing combinations in the neoadjuvant treatment of locally advanced and locally
recurrent breast carcinoma. A randomized phase II trial.
Breast Cancer Res. Treat.56: 125-132, 1999. IF=4.696)
Cocconi G., Bella M.A., Lottici R., Leonardi F., Ceci G., Passalacqua R., Di Blasio B., Bordi C., Biscottini B.,
Melpignano M., De Biasi D., Finardi C., Bacchi M.:
Mature results of a prospective randomized trial comparing two different time schedule of cisplatin in advanced ovarian
carcinoma.
American Journal of Clinical Oncology 22: 559-567, 1999. (IF=2.206)
Cocconi G., Bisagni G., Bella M., Acito L., Anastasi P., Carpi A., Di Costanzo F., Frassoldati A., Mosconi A., Borrini A.,
Buzzi P.
Comparison of CMF (Cyclophosphamide, Methotrexate, and 5-Fluorouracil) with a rotational crossing and a sequential
intensification regimen in advanced breast cancer. A prospective randomized trial.
American Journal of Clinical Oncology 22: 593-600, 1999. (IF=2.206)
Boni C., Bisagni G., Savoldi L., Moretti G., Rondini E., Sassi M., Zadro A., De Pas T., Franciosi V., Pazzola A., Vignoli
R., Banzi M.C., Pajetta V.
Gemcitabine, Ifosfamide, Cisplatin (GIP) for the treatment of advanced non-small cell lung cancer: a phase II study of the
Italian Oncology Group for Clinical Research (GOIRC).
International Journal of Cancer 87: 724-727, 2000. (IF=4.722)
Di Costanzo F., Canaletti R., Sdrobolini A., Olmeo N., Luppi G., Pucci F., Cavicchi F., Gasperoni S.,
Rodinò C., Zironi S., Angiona S., Contu A.
Modulation of fluorouracil by methotrexate, leucovorin and cisplatin (M-FLP) in the treatment of advanced pancreatic
cancer: a phase II study of the Italian Oncology Group for Clinical Research (GOIRC).
American Journal of Clinical Oncology 23 (3): 314-318, 2000. (IF=2.206)
Zeuli M., Pino M.S., Cognetti F.
La capecitabina nel trattamento del carcinoma colorettale.
Tumori 87 (1 suppl. 1): 55-56, 2001. (IF=0.863)
Zeuli M., Di Costanzo F., Sdrobolini A., Gasperoni S., Paoloni F.P., Carpi A., Moscetti L., Cherubini R., Cognetti F. on
behalf of Gruppo Oncologico Italiano per la Ricerca Clinica (GOIRC) e Gruppo Oncologico Laziale (GOL).
Capecitabine and oxaliplatin in advanced colorectal cancer: a dose-finding study.
Annals of Oncology 12: 1737-1741, 2001 (IF=5.647)
Cocconi G., Di Blasio B., Boni C., Bisagni G., Ceci G., Rondini E., Bella M., Leonardi F., Savoldi L., Camisa R., Bruzzi
P.
Randomized trial comparing cyclophosphamide, methotrexate, and 5-fluorouracil (CMF) with rotational CMF,
epirubicin and vincristine as primary chemotherapy in operable breast carcinoma.
Cancer 95: 228-235, 2002. (IF=5.418)
Colozza M., Bisagni G., Mosconi A. M., Gori S., Boni C., Sabbatini R., Frassoldati A., Passalacqua R., Rosa Bian A.,
Rodinò C., Rondini E., Algeri R., Di Sarra S., De Angelis V., Cocconi G., Tonato M., on behalf of the Italian Oncology
Group for Clinical Research (GOIRC).
Epirubicin versus CMF as adjuvant therapy for stage I and II breast cancer: a prospective randomised study.
European Journal of Cancer 38: 2279-2288, 2002. (IF=4.121).
Cocconi G., Passalacqua R., Foladore S., Carlini P., Acito L., Maiello E., Marchi M., Gebbia V., Di Sarra S., Beretta M.,
Bacchi M.
Treatment of metastatic malignant melanoma with dacarbazine plus tamoxifen, or vindesine plus tamoxifen: a
prospective randomized study.
Melanoma Research 13: 73-79, 2003. (IF=2.061)
G. Cocconi, P. Carlini, A. Gamboni, S. Gasperoni, C. Rodinò, S. Zironi, G. Bisagni, S. Porrozzi, F. Cognetti, F. Di
Costanzo, R. Canaletti, E. M. Ruggeri, R. Camisa, F. Pucci.
Cisplatin, epirubicin, leucovorin and 5-fluorouracil (PELF) is more active than 5-fluorouracil, doxorubicin and
methotrexate (FAMTX) in advanced gastric carcinoma.
Annals of Oncology 14: 1258-1263, 2003. (IF=5.647)
5
G. Cocconi.
Adjuvant chemotherapy in early breast cancer: optimal and suboptimal anthracycline-containing regimens.
Breast Cancer Research and Treatment 80: 313-320, 2003. (IF=4.696)
Di Costanzo F, Sobrero A, Gasperoni S, Dogliotti L, Frassineti L, Falcone A, Lionetto R, Bruzzi P, Luppi G, Gallo L,
Conte P, Comandone A, Turci D, Marzola M, Folco U, Pfanner E, Mestriner M, Boni C, Galli C, Tonato M, Rosso R;
Italian National Intergroup of Adjuvant Chemotherapy in Colon Cancer (INTACC).
Adjuvant chemotherapy in the treatment of colon cancer: randomized multicenter trial of the Italian National Intergroup
of Adjuvant Chemotherapy in Colon Cancer (INTACC).
Annals of Oncology 14:1365-72, 2003. (IF=5.647)
RC Coombes, E Hall, LJ Gibson, M Phil, R Paridaens, J Jassem, T Delozier, SE Jones, I Alvarez, G Bertelli, O Ortmann,
AS Coates, E Bajetta, D Dodwell, RE Coleman, LJ Fallowfield, E Mickiewicz, J Andersen, PE Lonning, G Cocconi, A
Stewart, N Stuart, CF Snowdon, M Carpentieri, G Massimini, JM Bliss for the Intergroup Exemestane Study.
A randomized trial of Exemestane after two to three years of Tamoxifen therapy in postmenopausal women with primary
brest cancer.
N Engl J Med 350: 1081-1092, 2004. (IF=47.050)
Di Costanzo F, Manzione L, Gasperoni S, Bilancia D, Acito L, Angiona S, Mazzoni F, Giustini L; Italian Oncology
Group for Cancer Research.
Paclitaxel and mitoxantrone in metastatic breast cancer: a phase II trial of the Italian Oncology Group for Cancer
Research.
Cancer Invest. 22 (3): 331-337, 2004. (IF=2.105)
Perrone F, Marangolo M, Di Costanzo F, Colucci G, Repetto L, Merlano M, De Placido S, Torri V, Comella G, Labianca
R, Parisi V, Gallo C.
Insurance for independent cancer trials.
Annals of Oncology 15 (11):1722-1723, 2004. (IF=5.647)
Sobrero A, Frassineti G, Falcone A, Dogliotti L, Rosso R, Di Costanzo F, Bruzzi P; INTACC.
Adjuvant sequential methotrexate --> 5-fluorouracil vs 5-fluorouracil plus leucovorin in radically resected stage III and
high-risk stage II colon cancer.
British Journal of Cancer 92 (1): 24-29, 2005.; errata corrige in Br J Cancer. 93: 733, 2005 (IF=4.346)
Di Costanzo F, Carlini P, Doni L, Massidda B, Mattioli R, Iop A, Barletta E, Moscetti L, Recchia F, Tralongo P,
Gasperoni S.
Gemcitabine with or without continuous infusion 5-FU in advanced pancreatic cancer: a randomised phase II trial of the
Italian Oncology Group for Clinical Research (GOIRC).
British Journal of Cancer 93 (2): 185-189, 2005. (IF=4.346)
G. Cocconi, B. Di Blasio, C. Boni, G. Bisagni, E. Rondini, M. A. Bella, F. Leonardi, L. Savoldi, C. Vallisneri, R. Camisa,
P. Bruzzi, on behalf of the Italian Oncology Group for Clinical Research (GOIRC).
Primary chemotherapy in operable breast carcinoma comparing CMF (cyclophosphamide, methotrexate, and
5-fluorouracil) with an anthracycline-containing regimen: short-term responses translated into long-term.
Annals of Oncology 16: 1469-1476, 2005 (IF=5.647)
Colozza M, Sidoni A, Mosconi AM, Cavaliere A, Bisagni G, Gori S, De Angelis V, Frassoldati A, Cherubini R, Bian AR,
Rodino C, Mazzocchi B, Mihailova Z, Bucciarelli E, Tonato M; Italian Oncology Group for Clincal Research.
HER2 overexpression as a predictive marker in a randomized trial comparing adjuvant
cyclophosphamide/methotrexate/5-fluorouracil with epirubicin in patients with stage I/II breast cancer: long-term results.
Clin Breast Cancer. 6(3): 253-9, 2005. (IF=2.065)
Perrone F, Marangolo M, Di Costanzo F, Colucci G, Repetto L, Merlano M, De Placido S, Torri V, Comella G, Labianca
R, Parisi V, Gallo C.
Cost of insurance policies for investigator-initiated cancer clinical trials in Italy
Tumori 91 (4): 373-373, 2005 (IF=0.863)
Di Costanzo F, Gasperoni S, Papaldo P, Bilancia D, Manzione L, Landucci E, Mazzoni F, Cognetti F.
Weekly paclitaxel plus capecitabine in advanced breast cancer patients: dose-finding trial of GOIRC and GOL.
Annals of Oncology 17 (1): 79-84, 2006 (IF=5.647)
6
Coombes RC, Kilburn LS, Snowdon CF, Paridaens R, Coleman RE, Jones SE, Jassem J, Van de Velde CJ, Delozier T,
Alvarez I, Del Mastro L, Ortmann O, Diedrich K, Coates AS, Bajetta E, Holmberg SB, Dodwell D, Mickiewicz E,
Andersen J, Lonning PE, Cocconi G, Forbes J, Castiglione M, Stuart N, Stewart A, Fallowfield LJ, Bertelli G, Hall E,
Bogle RG, Carpentieri M, Colajori E, Subar M, Ireland E, Bliss JM; Intergroup Exemestane Study.
Survival and safety of exemestane versus tamoxifen after 2-3 years' tamoxifen treatment (Intergroup Exemestane Study):
a randomised controlled trial.
Lancet 369 (9561): 559-70, 2007; Erratum in: Lancet 369 (9565): 906, 2007. (IF=30.758)
Dalla Chiesa M, Passalacqua R, Michiara M, Franciosi V, Di Costanzo F, Bisagni G, Camisa R, Buti S, Tommasello G,
Cocconi G; Italian Oncology Group for Clinical Research.
Tamoxifen vs Tamoxifen plus 13-cis-retinoic acid vs Tamoxifen plus Interferon alpha-2a as first-line endocrine
treatments in advanced breast cancer: updated results of a phase II, prospective, randomised multicentre trial.
Acta Biomed 78 (3): 204-209, 2007
Di Costanzo F, Gasperoni S, Manzione L, Bisagni G, Labianca R, Bravi S, Cortesi E, Carlini P, Bracci R, Tomao S,
Messerini L, Arcangeli A, Torri V, Bilancia D, Floriani I, Tonato M; On behalf of Italian Oncology Group for Cancer
Research.
Adjuvant Chemotherapy in Completely Resected Gastric Cancer: A Randomized Phase III Trial Conducted by GOIRC.
J Natl Cancer Inst 100 (6): 388-398, 2008. (IF=14.069)
Passalacqua R, Buzio C, Buti S, Porta C, Labianca R, Pezzuolo D, Camisa R, Sabbatini R, Benecchi L, Messina C,
Cengarle R, Vaglio A, Dalla Chiesa M, Tomasello G, Caminiti C.
Phase III, randomised, multicentre trial of maintenance immunotherapy with low-dose interleukin-2 and interferon-alpha
for metastatic renal cell cancer.
Cancer Immunol Immunother 59: 553–561, 2010 (IF=3.791)
Colucci G, Labianca R, Di Costanzo F, Gebbia V, Cartenì G, Massidda B, Dapretto E, Manzione L, Piazza E, Sannicolò
M, Ciaparrone M, Cavanna L, Giuliani F, Maiello E, Testa A, Pederzoli P, Falconi M, Gallo C, Di Maio M, and Perrone
F. Gruppo Oncologico Italia Meridionale (GOIM); Gruppo Italiano per lo Studio dei Carcinomi dell'Apparato Digerente
(GISCAD); Gruppo Oncologico Italiano di Ricerca Clinica (GOIRC).
Randomized Phase III Trial of Gemcitabine Plus Cisplatin Compared With Single-Agent Gemcitabine As First-Line
Treatment of Patients With Advanced Pancreatic Cancer: The GIP-1 Study.
J Clin Oncol 28 (10): 1645-51, 2010 (IF=17.793)
Buti S, Lazzarelli S, Chiesa MD, Simonelli C, Lo Re G, Lheshi A, Simon S, Mattioli R, Caminiti C, Mazza G, Donini M,
Passalacqua R; from the GOIRC (Italian Oncology Group for Clinical Research).
Dose-finding Trial of a Combined Regimen With Bevacizumab, Immunotherapy, and Chemotherapy in Patients With
Metastatic Renal Cell Cancer: An Italian Oncology Group for Clinical Research (GOIRC) Study.
J Immunother 33 (7): 735-41, 2010 (IF=3.203)
Giorgio Cocconi, Corrado Boni, Maurizio Tonato, Rodolfo Passalacqua, Mariantonietta Colozza, Anna M. Mosconi,
Giancarlo Bisagni, Ermanno Rondini, Lina Rodinò, Amalia Carpi, Francesco Di Costanzo, Mauro Brugia, Giuseppe
Attardo, Luigi Acito, Riccardo Rossetti, Maria Bella, Roberta Camisa, Francesco Cardinale, Beatrice Dozin.
Randomized Trial Comparing Cyclophosphamide, Methotrexate, and 5-Fluorouracil (CMF) Regimen with Rotational
CMFEV Regimen (E = Epirubicin, V = Vincristine) as Adjuvant Chemotherapy in Moderate Risk Operable Breast
Carcinoma.
Journal of Cancer Therapy 2, 342-353, 2011. (IF=0.14)
Emiel Rutgers, Martine J. Piccart-Gebhart, Jan Bogaerts, Suzette Delaloge, Laura Van ‘t Veer, Isabel Teresa Rubio,
Giuseppe Viale, Alastair M. Thompson, Rodolfo Passalacqua, Ulrike Nitz, Anita Vindevoghel, Jean-Yves Pierga, Peter
M. Ravdin, Gustavo Werutsky, Fatima Cardoso.
The EORTC 10041/BIG 03-04 MINDACT trial is feasible: Results of the pilot phase
European Journal of Cancer 47: 2742–2749, 2011
Boni C, Tiseo M, Boni L, Baldini E, Recchia F, Barone C, Grossi F, Germano D, Matano E, Marini G, Labianca R, Di
Costanzo F, Bagnulo A, Pennucci C, Caroti C, Mencoboni M, Zanelli F, Prochilo T, Cafferata MA, Ardizzoni A; Gruppo
Oncologico Italiano di Ricerca Clinica (GOIRC).
Triplets versus doublets, with or without cisplatin, in the first-line treatment of stage IIIB-IV non-small cell lung cancer
(NSCLC) patients: a multicenter randomised factorial trial (FAST).
Br J Cancer 106 (4): 658-65, 2012
7
Marcello Tiseo, Elisa Giovannetti, Carmelo Tibaldi, Andrea Camerini, Francesco Di Costanzo, Fausto Barbieri, Jacobus
A. Burgers, Andrew Vincent, Godefridus J. Peters, Egbert F. Smit, Andrea Ardizzoni.
Pharmacogenetic study of patients with advanced non-small cell lung cancer (NSCLC) treated with second-line
pemetrexed or pemetrexed–carboplatin.
Lung Cancer 78: 92– 99, 2012
Andrea Ardizzoni, Marcello Tiseo, Luca Boni, Andrew D Vincent, Rodolfo Passalacqua, Sebastiano Buti, Domenico
Amoroso, Andrea Camerini, Roberto Labianca, Giovenzio Genestreti, Corrado Boni, Libero Ciuffreda, Francesco Di
Costanzo, Filippo de Marinis, Lucio Crino, Antonio Santo, Andrea Pazzola, Fausto Barbieri, Nicoletta Zilembo, Ida
Colantonio, Carmelo Tibaldi, Rodolfo Mattioli, Mara A Cafferata, Roberta Camisa, and Egbert F Smit
Pemetrexed versus pemetrexed and carboplatin as second-line chemotherapy in advanced non-small-cell lung cancer
(NSCLC): results of GOIRC 02-2006 randomized phase II study and pooled analysis with NVALT7 trial.
J Clin Oncol 30(36): 4501-7, 2012(IF=17.793)
Sergio Bracarda, Camillo Porta, Corrado Boni, Armando Santoro, Claudia Mucciarini, Antonio Pazzola, Enrico Cortesi,
Donatello Gasparro, Roberto Labianca, Francesco Di Costanzo, Alfredo Falcone, Michela Cinquini, Claudia Caserta,
Chiara Paglino, Verena De Angelis.
Could Interferon Still Play a Role in Metastatic Renal Cell Carcinoma? A Randomized Study of Two Schedules of
Sorafenib Plus Interferon-Alpha 2a (RAPSODY).
European Urology 63: 254-261, 2013
Bisagni G, Musolino A, Panebianco M, De Matteis A, Nuzzo F, Ardizzoni A, Gori S, Gamucci T, Passalacqua R, Gnoni
R, Moretti G, Boni C.
The Breast Avastin Trial: phase II study of bevacizumab maintenance therapy after induction chemotherapy with
docetaxel and capecitabine for the first-line treatment of patients with locally recurrent or metastatic breast cancer.
Cancer Chemother Pharmacol. 2013 Apr;71(4):1051-7
Tiseo M, Bordi P, Bortesi B, Boni L, Boni C, Baldini E, Grossi F, Recchia F, Zanelli F, Fontanini G, Naldi N, Campanini
N, Azzoni C, Bordi C, Ardizzoni A.
ERCC1/BRCA1 expression and gene polymorphisms as prognostic and predictive factors in advanced NSCLC treated
with or without cisplatin.
Br J Cancer. 2013 Apr 30;108(8):1695-703
Mazzoni F, Cecere FL, Meoni G, Giuliani C, Boni L, Camerini A, Lucchesi S, Martella F, Amoroso D, Lucherini E,
Torricelli F, Di Costanzo F.
Phase II trial of customized first line chemotherapy according to ERCC1 and RRM1 SNPs in patients with advanced
non-small-cell lung cancer.
Lung Cancer. Nov; 82(2): 288-93, 2013. (IF=3.392)
Bajetta E, Floriani I, Di Bartolomeo M, Labianca R, Falcone A, Di Costanzo F, Comella G, Amadori D, Pinto C,
Carlomagno C, Nitti D, Daniele B, Mini E, Poli D, Santoro A, Mosconi S, Casaretti R, Boni C, Pinotti G, Bidoli P, Landi
L, Rosati G, Ravaioli A, Cantore M, Di Fabio F, Aitini E, Marchet A; ITACA-S (Intergroup Trial of Adjuvant
Chemotherapy in Adenocarcinoma of the Stomach Trial) Study Group.
Randomized trial on adjuvant treatment with FOLFIRI followed by docetaxel and cisplatin versus 5-fluorouracil
and folinic acid for radically resected gastric cancer.
Ann Oncol. 2014 Jul;25(7):1373-8
Passalacqua R, Caminiti C, Buti S, Porta C, Camisa R, Braglia L, Tomasello G, Vaglio A, Labianca R, Rondini E,
Sabbatini R, Nastasi G, Artioli F, Prati A, Potenzoni M, Pezzuolo D, Oliva E, Alberici F, Buzio C; for the POLAR-01
Trial Investigators.
Adjuvant Low-Dose Interleukin-2 (IL-2) Plus Interferon-α (IFN-α) in Operable Renal Cell Carcinoma (RCC): A
Phase III, Randomized, Multicentre Trial of the Italian Oncology Group for Clinical Research (GOIRC).
J Immunother. November/December;37 (9):440-447, 2014.